Brain Aging and Treatment Response in Geriatric Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 23, 2019

Study Completion Date

January 23, 2019

Conditions
Mild Cognitive Impairment (MCI)Depression
Interventions
DRUG

Escitalopram

All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.

DRUG

Memantine

Memantine dosage will be 5 to 20mg a day. Participants will initially take one 5mg capsule once a day, which will be gradually increased to a maximum of 10mg capsules twice per day.

DRUG

Placebo

Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.

Trial Locations (1)

90095

UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los Angeles

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of California, Los Angeles

OTHER

NCT01902004 - Brain Aging and Treatment Response in Geriatric Depression | Biotech Hunter | Biotech Hunter